Literature DB >> 24426330

Down syndrome with different hematological manifestations: a short series of 3 cases with review of literature.

Prabhu Manivannan1, Priavadhana Rajan Prasaad1, Rakhee Kar1, Debdatta Basu1.   

Abstract

Children with Down syndrome (DS) present with a spectrum of hematolymphoid malignancies ranging from transient myeloproliferative disorder (TMD) which regress spontaneously to frank acute leukemia of both myeloid and lymphoid lineage. Here we present a series of three cases with different manifestation in DS. Three cases of DS presented with TMD, acute myeloid leukemia (AML-M2) and acute megakaryoblastic leukemia (AMKL), respectively. This case series displays the spectrum of hematological manifestations in children with DS. Although TMD and AMKL are strongly associated with DS, other AML subtypes can also be seen in such patients.

Entities:  

Keywords:  Acute megakaryoblastic leukemia; Acute myeloid leukemia; Down syndrome; Transient myeloproliferative disorder

Year:  2012        PMID: 24426330      PMCID: PMC3572257          DOI: 10.1007/s12288-011-0134-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  11 in total

Review 1.  Down's syndrome.

Authors:  Nancy J Roizen; David Patterson
Journal:  Lancet       Date:  2003-04-12       Impact factor: 79.321

2.  Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome.

Authors:  A Zipursky; E Brown; H Christensen; R Sutherland; J Doyle
Journal:  Semin Perinatol       Date:  1997-02       Impact factor: 3.300

3.  GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.

Authors:  Yubin Ge; Mark L Stout; Dana A Tatman; Tanya L Jensen; Steven Buck; Ronald L Thomas; Yaddanapudi Ravindranath; Larry H Matherly; Jeffrey W Taub
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

4.  Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis.

Authors:  N J Karandikar; D B Aquino; R W McKenna; S H Kroft
Journal:  Am J Clin Pathol       Date:  2001-08       Impact factor: 2.493

Review 5.  Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome.

Authors:  A Zipursky; E J Brown; H Christensen; J Doyle
Journal:  Clin Lab Med       Date:  1999-03       Impact factor: 1.935

Review 6.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

7.  Natural history of GATA1 mutations in Down syndrome.

Authors:  Momin Ahmed; Alexander Sternberg; Georgina Hall; Angela Thomas; Owen Smith; Aengus O'Marcaigh; Robert Wynn; Richard Stevens; Michael Addison; Derek King; Barbara Stewart; Brenda Gibson; Irene Roberts; Paresh Vyas
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

8.  Congenital leukaemia in Down Syndrome--a case report.

Authors:  Moatoshi Aier; Thangura Zadeng; Debdatta Basu; Niranjan Biswal; P Nalini
Journal:  Indian J Pathol Microbiol       Date:  2002-07       Impact factor: 0.740

Review 9.  Transient leukemia with trisomy 21: description of a case and review of the literature.

Authors:  S Bhatt; R Schreck; J M Graham; J R Korenberg; C G Hurvitz; N Fischel-Ghodsian
Journal:  Am J Med Genet       Date:  1995-09-25

10.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.

Authors:  Gita V Massey; Alvin Zipursky; Myron N Chang; John J Doyle; Suhail Nasim; Jeffrey W Taub; Yaddanapudi Ravindranath; Gary Dahl; Howard J Weinstein
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.